Recombinant tissue plasminogen activator for the treatment of acute ischemic stroke
Jennifer M. Roth, PharmD, BCPS The use of recombinant tissue plasminogen activator (rtPA) has been the standard of care for treatment of acute ischemic stroke for several years. Studies evaluating the efficacy, safety, and optimal timing of rtPA use are ongoing. Recently, results of new studies led to expansion of the short timeframe from stroke symptom onset in which a patient can receive this treatment. Additionally, more data are available to support the current goals of administration of rtPA to eligible patients as quickly as possible, as earlier treatment has been proven to improve outcomes. linical practice guidelines published by both the American Heart Association and American Stroke Association (AHA/ASA) in 2007, and the American College of Chest Physicians in 2008, recommend the use of the thrombolytic agent recombinant tissue plasminogen activator (rtPA) for the treatment of acute ischemic stroke (AIS) in eligible patients (1, 2) . Approved by the US Food and Drug Administration (FDA) in 1996 for treatment of AIS, intravenous rtPA (or alteplase) is the only thrombolytic agent approved for this indication to date (3). Due to the extremely small timeframe in which a patient is eligible to receive rtPA, it is estimated that only 3% to 5% of stroke sufferers reach a hospital in time to be considered for this treatment (4) . Th is small number is discouraging because "the ultimate goal of early reperfusion therapy is to reduce or prevent brain infarction and thereby minimize the long term disability, neurologic impairment, and stroke-related mortality" (2) . As stroke is the third most frequent cause of death in the USA, killing 137,000 people each year, mortality reduction could potentially spare the lives of a large number of patients (5) . Th is article briefl y reviews the evidence supporting the use of rtPA for AIS and focuses on important new literature that has impacted practice since the publication of the current AIS guidelines.
BACKGROUND
The initial European Cooperative Acute Stroke Study (ECASS), published in 1995, studied rtPA at a higher dose (1.1 mg/kg, maximum dose 100 mg) and in a longer timeframe from stroke symptom onset (within 6 hours) than in subsequent studies, which led to currently approved and accepted rtPA dosing and usage criteria (6) . Th e multicenter trial was conducted in 75 European hospitals and included 620 patients. In ECASS, rtPA
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was not found to be more eff ective than placebo in improving neurological outcomes at 3 months; however, post hoc analysis showed benefi t in patients treated within 3 hours of stroke symptom onset, but not in those treated beyond that timeframe.
Also published in 1995, the National Institute of Neurological Disorders and Stroke rtPA Stroke Study evaluated 624 patients in the USA who were randomized to the current FDA-approved dose (0.9 mg/kg, maximum dose 90 mg) or placebo within 3 hours of stroke symptom onset (7) . Patients who received rtPA were at least 30% more likely to have minimal or no disability at 3 months based on four assessment scales when compared to those in the placebo group. Symptomatic intracerebral hemorrhage (ICH) within 36 hours occurred in 6.4% of rtPA patients versus 0.6% of placebo patients (P < 0.001), and mortality was similar in both groups at 3 months (P = 0.30). Of note, half of the study patients were treated within 90 minutes of stroke symptom onset. A later subgroup analysis of the trial demonstrated that treatment with rtPA within 90 minutes of stroke symptom onset resulted in more favorable outcomes (odds ratio [OR], 2.11; 95% confi dence interval [CI], 1.33-3.55) when compared to rtPA initiated within 90 to 180 minutes (OR, 1.69; 95% CI, 1.09-2.62) (8) .
EXPANDED CRITERIA FOR rtPA USE
As mentioned above, the short 3-hour timeframe in which a patient is eligible for treatment with rtPA is a major contributing factor to the relatively small number of patients who receive this medication (4) . When the European Medicines Agency approved use of rtPA in Europe in 2002, the agency requested that two follow-up studies be conducted. Conducted fi rst, the SITS-MOST trial confi rmed rtPA to be as safe and eff ective within 3 hours of onset of AIS in practice as in trials (9) .
Th e second follow-up study evaluated the use of rtPA beyond the 3-hour timeframe. ECASS III, a double-blind, multicenter, parallel-group trial conducted between July 2003 and November 2007 (10), included patients 18 to 80 years of age with a clinical diagnosis of stroke who were able to receive the C study drug within 3 to 4 hours of stroke symptom onset. After 2 years, the trial was amended to include patients treated within a 4.5-hour window, based on the results of a pooled analysis that suggested a benefi t of rtPA treatment in this timeframe, as well as slow enrollment in the 3-to 4-hour window (11) . A total of 821 patients were randomized to receive either rtPA or placebo, with the primary effi cacy endpoint being disability at 90 days (dichotomized as a favorable outcome [score 0 or 1] or unfavorable outcome [score 2-6]), as assessed by modifi ed Rankin scale). As a secondary effi cacy endpoint, the study evaluated a combination of global outcome measures. Safety endpoints were mortality at 90 days, any ICH, symptomatic ICH, and other adverse events. Four hundred patients were required in each group to reach 90% power to detect an OR of 1.4 for the primary endpoint. For the intentto-treat analysis, 418 patients were randomized to receive rtPA and 403 were randomized to receive placebo.
Two hundred nineteen (52.4%) patients who received rtPA, compared to 182 (45.2%) patients who received placebo, had a favorable outcome (P = 0.04). Th ese results were also found to be signifi cant in the post hoc intent-to-treat analysis. Outcomes were more favorable for rtPA versus placebo for the secondary endpoint, which showed that 28% more patients in the rtPA group were able to return to an independent lifestyle. Th irty-two (7.7%) patients in the rtPA group died, and 34 (2.9%) in the placebo group died. Mortality was not significantly diff erent between the two groups (P = 0.68). ICH occurred in 27% of patients in the rtPA group versus 17.6% of patients in the placebo group (P = 0.001), with symptomatic ICH in 2.4% and 0.3% of each group, respectively (P = 0.008). Th e median overall time to rtPA administration was 3 hours, 59 minutes.
Concurrently, the SITS-MOST study investigators published results from their ongoing stroke registry, called SITS-ISTR, which also demonstrated benefi t to using rtPA within 3 to 4.5 hours from stroke symptom onset (12) .
Based on the results of the ECASS III and SITS-ISTR trials, the AHA/ASA published a science advisory statement in 2009 recommending that rtPA should be administered to eligible patients within 3 to 4.5 hours after onset of stroke symptoms (Class I, Level B evidence) (13) . It is important to note, however, that the extended window for rtPA administration is not recommended for several patient populations, as there is currently no data to support its use in these patients. Th ey include those older than 80 years; those receiving anticoagulant therapy, even with an international normalized ratio ≤1.7; those with a baseline National Institutes of Health Stroke Scale score >25; and those with a history of both a prior stroke and diabetes. Patients meeting one or more of these criteria are not considered candidates to receive rtPA, even if otherwise eligible, if it would be initiated >3 hours from stroke symptom onset. (See Table  for full list of indications and contraindications.)
60-MINUTE DOOR-TO-NEEDLE
Current guidelines recommend that institutions treating AIS patients with rtPA do so with a goal of a door-to-needle time of • On an anticoagulant, with an international normalized ratio >1.7 (warfarin) or elevated partial thromboplastin time (heparin)
• Platelet count <100,000 uL • Serum glucose <50 mg/dL or >400 mg/dL • Pregnancy
Relative contraindications
• Large stroke with National Institutes of Health Stroke Scale score >22
• Findings, on computed tomography of the head, of early infarct involving more than one third of the middle cerebral artery territory Additional exclusions for treatment 3 to 4.5 hours after stroke symptom onset
• Age >80 years • History of stroke and diabetes mellitus • Any anticoagulant use prior to admission (even if international normalized ratio <1.7)
• Pretreatment stroke score >25
• Findings, on computed tomography of the head, of early infarct involving more than one third of the middle cerebral artery territory ≤60 minutes. Data from the AHA/ASA national stroke registry, Get With the Guidelines-Stroke, were evaluated by Fonarow and colleagues to determine how often door-to-needle times ≤60 minutes are achieved, as well as patient and hospital characteristics and temporal trends in this patient group (with data analysis including only patients treated within 3 hours of stroke symptom onset) (14) . In patients with a door-to-needle time ≤60 minutes, the unadjusted mortality rate was 8.6%, versus 10.4% for those in the door-to-needle >60 minute group (P < 0.0001). Overall complication rates and ICH rates were lower in those patients treated within 60 minutes. One of the most compelling fi ndings of this study came from analysis of the door-to-needle time as a continuous variable in relation to in-hospital mortality. For every 15-minute reduction in door-to-needle time, there was a 5% lower odds of mortality (adjusted OR, 0.95; 95% CI, 0.92-0.98; P = 0.0007). Th e authors noted that these results should be interpreted cautiously, as they have not been reported previously and should be further replicated.
DISCUSSION
Since publication of the most recent guidelines for treatment of AIS in 2008, several studies have contributed to the growing body of literature supporting use of rtPA. Th e results of ECASS III and SITS-ISTR published in 2008, and later supported by a science advisory statement from the AHA/ASA, provided potential expanded eligibility for rtPA use. However, for several patient populations, use of rtPA 3 to 4.5 hours from stroke symptom onset has not been studied and therefore is not currently recommended.
Both previous literature and now the results of the data evaluated by Fonarow and colleagues confi rm that outcomes and mortality are better in patients who receive rtPA as soon as possible after stroke symptom onset. Door-to-needle times of ≤60 minutes in stroke registry patients have increased from 19.5% in 2003 to 29.1% in 2009, an increase of about 1.6% per year (14) . With more stroke centers being established and the continued focus for all stroke centers to meet the goal of timely rtPA administration, it is likely that AIS outcomes will continue to improve in the coming years.
